DigiClinics tackles India’s biggest cancer challenge—<2% breast screening and severe pathology shortages—by building a FullStack AI Oncology platform. We deliver ScreeningAI for USG BI-RADS, PathologyAI trained on 1.1M+ tiles for Nottingham & ER/PR/HER2, and BrCAI-Nexus biomarkers for therapy and CDx. With PHC-ready workflows, 18-min grading, and NASSCOM CoE incubation, we provide affordable, scalable precision diagnostics for India.

Extracted from Digiclinics Research & Services Private Limited's own website, fetched Jul 2026. Verification badges reflect format/MX checks, not endorsement.